Expertise in
52
conditions

Dr. Vinod Parameswaran

Hematology | Oncology
Avera Medical Group Hematology
1000 E 23rd St Ste 200, 
Sioux Falls, SD 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Expertise in
52
conditions
Avera Medical Group Hematology
1000 E 23rd St Ste 200, 
Sioux Falls, SD 

Overview

Vinod Parameswaran is a Hematologist and an Oncologist practicing medicine in Sioux Falls, South Dakota.

Dr. Parameswaran is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Multiple Myeloma, Thrombocytopenia, Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 8 clinical trials. Dr. Parameswaran is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in SD

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Avera Health
  • HMO
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
DAKOTACARE
  • HMO
  • INSURANCE PLAN
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Primewest Health System
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Sanford
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 11 Less Insurance Carriers -

Locations

Avera Medical Group Hematology
1000 E 23rd St Ste 200, Sioux Falls, SD 57105

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Enrollment Status: Recruiting
Publish Date: August 19, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide
Study Phase: Phase 3
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Enrollment Status: Recruiting
Publish Date: August 19, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Daratumumab, Dexamethasone, Lenalidomide
Study Phase: Phase 3
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
Managed Access Programs for CTL019, Tisagenlecleucel
Managed Access Programs for CTL019, Tisagenlecleucel
Enrollment Status: Available
Publish Date: April 23, 2026
Intervention Type: Biological
The National Myelodysplastic Syndromes Natural History Study
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Completed
Publish Date: February 03, 2026
Intervention Type: Other
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Approved_for_marketing
Publish Date: June 07, 2022
Intervention Type: Drug
View 6 Less Clinical Trials

4 Total Publications

Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial.
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial.
Journal: Leukemia & lymphoma
Published: June 05, 2024
Similar Doctors
Expertise in
49
conditions
Dr. Christopher J. Sumey
Oncology | Hematology
Expertise in
49
conditions
Dr. Christopher J. Sumey
Oncology | Hematology
Referral may be required

Sanford Cancer Center

1309 W. 17th St., 
Sioux Falls, SD 
 (1.3 miles away)
605-328-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Christopher Sumey practices hematology and oncology in Sioux Falls, South Dakota. He treats all subtypes of cancer and hematologic conditions. He has a particular interest in genitourinary malignancies, including those of the: Speaks: English. Dr. Sumey is highly rated in 49 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Lung Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Sumey is board certified in American Board Of Internal MedicineAmerican Board Of Internal Medicine: Medical OncologyAmerican Board Of Internal Medicine: Hematology. Dr. Sumey is currently accepting new patients.

Expertise in
68
conditions
Dr. Jonathan S. Bleeker
Hematology | Oncology
Expertise in
68
conditions
Dr. Jonathan S. Bleeker
Hematology | Oncology
Referral may be required

Sanford Luverne Clinic

1601 Sioux Valley Drive, 
Luverne, MN 
 (28.3 miles away)
507-283-4476
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Jonathan Bleeker specializes in oncology and hematology. He focuses on bringing the latest in cancer research to his patients. Speaks: English. Dr. Bleeker is highly rated in 68 conditions, according to our data. His clinical expertise encompasses Ataxia-Pancytopenia Syndrome, Fanconi Anemia, Shwachman-Diamond Syndrome, Pancreatic Cancer, and Bone Marrow Aspiration. Dr. Bleeker is board certified in American Board Of Internal Medicine: Medical OncologyAmerican Board Of Internal Medicine: HematologyAmerican Board Of Internal Medicine: Internal Medicine. Dr. Bleeker is currently accepting new patients.

Expertise in
38
conditions
Dr. Steven F. Powell
Hematology | Oncology
Expertise in
38
conditions
Dr. Steven F. Powell
Hematology | Oncology
Referral may be required

Sanford Cancer Center

1309 W. 17th St., 
Sioux Falls, SD 
 (1.3 miles away)
605-328-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Steven Powell is an oncology and hematology physician who specializes in treating lung, head and neck cancer and melanoma. He is an active investigator on numerous clinical trials. Dr. Powell also runs a research lab that gives patients access to novel immunotherapy treatments for head and neck cancer. Listen to Dr. Steven Powell on Sanford Health’s Innovations podcast where he discusses fighting cancer with personalized medicine . Speaks: English. Dr. Powell is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Olfactory Neuroblastoma, Pleuropulmonary Blastoma, Melanoma, and Bone Marrow Aspiration. Dr. Powell is board certified in American Board Of Internal Medicine: HematologyAmerican Board Of Internal Medicine: OncologyAmerican Board Of Internal Medicine: Internal Medicine. Dr. Powell is currently accepting new patients.

Frequently Asked Questions about Dr. Vinod Parameswaran

How do I make an appointment with Dr. Vinod Parameswaran?

You can book an appointment with Dr. Vinod Parameswaran by calling their office at 605-322-3035. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Vinod Parameswaran a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Vinod Parameswaran is classified as an Distinguished expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Vinod Parameswaran specialize in?

While Dr. Vinod Parameswaran is a Hematology, they have specific expertise in Non-Hodgkin Lymphoma, Multiple Myeloma, and Thrombocytopenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Vinod Parameswaran participate in research or clinical trials?

Yes. Dr. Vinod Parameswaran has published 4 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Vinod Parameswaran's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Vinod Parameswaran accept my insurance?

Dr. Vinod Parameswaran accepts most major insurance plans, including Aetna and Avera Health. We recommend calling the office directly at 605-322-3035 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Parameswaran's expertise for a condition
ConditionClose
    View All 19 Distinguished Conditions
    View All 33 Advanced Conditions
    View All 49 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile